Missense substitutions associated with behavioural disturbances in Alzheimer's disease (AD)

Brain Research Bulletin

Volumn 88, Issue 5, 2012, Pages 394-405

  Proitsi, Petroula ^a   Powell, John F ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's Disease; Bevioural; BPSD; Genetics; Missense substitution; Psychiatric; SNP

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NEU DIFFERENTIATION FACTOR; SEROTONIN 2 RECEPTOR;

AGITATION; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; DELUSION; DEPRESSION; EATING DISORDER; GENETIC ASSOCIATION; HALLUCINATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; HUMANS; MENTAL DISORDERS; MUTATION, MISSENSE; PHENOTYPE; RISK FACTORS; STRESS, PSYCHOLOGICAL;

EID: 84862528468     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.02.010     Document Type: Article

References (103)

1. Aalten P., Verhey F.R., Boziki M., Bullock R., Byrne E.J., Camus V., Caputo M., Collins D., De Deyn P.P., Elina K., Frisoni G., Girtler N., Holmes C., Hurt C., Marriott A., Mecocci P., Nobili F., Ousset P.J., Reynish E., Salmon E., Tsolaki M., Vellas B., Robert P.H. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement. Geriatr. Cogn. Disord. 2007, 24:457-463.
2. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7:248-249.
3. ano-Wood L., Houston W.S., Emond J.A., Marchant N.L., Salmon D.P., Jeste D.V., Thal L.J., Bondi M.W. APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study. Int. J. Geriatr. Psychiatry 2008, 23:632-636.
4. Aparasu R.R., Mort J.R. Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. Am. J. Geriatr. Pharmacother. 2004, 2:102-111.
5. Assal F., Alarcon M., Solomon E.C., Masterman D., Geschwind D.H., Cummings J.L. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch. Neurol. 2004, 61:1249-1253.
6. AXELROD J., TOMCHICK R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 1958, 233:702-705.
7. Ballard C., Massey H., Lamb H., Morris C. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1997, 63:273-274.
8. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
9. Borroni B., Agosti C., Archetti S., Costanzi C., Bonomi S., Ghianda D., Lenzi G.L., Caimi L., Di L.M., Padovani A. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci. Lett. 2004, 370:127-129.
10. Borroni B., Grassi M., Agosti C., Costanzi C., Archetti S., Franzoni S., Caltagirone C., Di L.M., Caimi L., Padovani A. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol. Aging 2006, 27:1595-1603.
11. Borroni B., Grassi M., Agosti C., Archetti S., Costanzi C., Cornali C., Caltagirone C., Caimi L., Di L.M., Padovani A. Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. Am. J. Geriatr. Psychiatry 2006, 14:343-351.
12. Borroni B., Grassi M., Costanzi C., Zanetti M., Archetti S., Franzoni S., Caimi L., Padovani A. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol. Aging 2007, 28:1231-1238.
13. Borroni B., Grassi M., Archetti S., Costanzi C., Bianchi M., Caimi L., Caltagirone C., Di L.M., Padovani A. BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J. Alzheimers Dis. 2009, 18:867-875.
14. Borroni B., Costanzi C., Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr. Alzheimer Res. 2010, 7:158-164.
15. Cacabelos R., Rodriguez B., Carrera C., Beyer K., Lao J.I., Sellers M.A. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer Dis. Assoc. Disord. 1997, 11(Suppl 4):S27-S34.
16. Cantillon M., Harwood D., Barker W., St George-Hyslop P., Tsuda T., Ekatarina R., Duara R. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease. Biol. Psychiatry 1997, 41:246-248.
17. Chang J.B., Wang P.N., Chen W.T., Liu C.Y., Hong C.J., Lin K.N., Liu T.Y., Chi C.W., Liu H.C. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology 2004, 63:1105-1107.
18. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
19. Chen C.S., Ouyang P., Yeh Y.C., Lai C.L., Liu C.K., Yen C.F., Ko C.H., Yen J.Y., Liu G.C., Juo S.H. Apolipoprotein E Polymorphism and Behavioral and Psychological Symptoms of Dementia in Patients With Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 2011.
20. Chopra M.P., Landes R.D., Jones R.A., Feldman Z.L., Beck C., Griffin S.T. Does the apolipoprotein E epsilon 4 genotype influence the expression of depression with cognitive impairment?. Int. J. Geriatr. Psychiatry 2009, 24:650-652.
21. Craig D., Hart D.J., McCool K., McIlroy S.P., Passmore A.P. Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:1327-1330.
22. Craig D., Hart D.J., Carson R., McIlroy S.P., Passmore A.P. Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci. Lett. 2004, 368:33-36.
23. Craig D., Hart D.J., Passmore A.P. Genetically increased risk of sleep disruption in Alzheimer's disease. Sleep 2006, 29:1003-1007.
24. Del P.M., Spaccavento S., Craca A., Fiore P., Angelelli P. Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease. Neurol. Sci. 2009, 30:367-373.
25. Donaldson C., Tarrier N., Burns A. The impact of the symptoms of dementia on caregivers. Br. J. Psychiatry 1997, 170:62-68.
26. D'Onofrio G., Panza F., Seripa D., Sancarlo D., Paris F., Cascavilla L., Urbano M., Gravina C., Fontana A., Solfrizzi V., Pellegrini F., Pilotto A. The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. Int. J. Geriatr. Psychiatry 2010.
27. Engelborghs S., Dermaut B., Marien P., Symons A., Vloeberghs E., Maertens K., Somers N., Goeman J., Rademakers R., Van den B.M., Pickut B., Cruts M., Van B.C., De Deyn P.P. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol. Aging 2006, 27:285-292.
28. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
29. Forsell Y., Corder E.H., Basun H., Lannfelt L., Viitanen M., Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+. Biol. Psychiatry 1997, 42:898-903.
30. Forsell Y., Basun H., Corder E.H., Lannfelt L., Winblad B. Psychotic symptoms and apolipoprotein E genotypes in an elderly population. Biol. Psychiatry 1998, 44:139-140.
31. Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., Lobo A., Martinez-Lage J., Soininen H., Hofman A. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S10-S15.
32. Funke B., Malhotra A.K., Finn C.T., Plocik A.M., Lake S.L., Lencz T., DeRosse P., Kane J.M., Kucherlapati R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain Funct. 2005, 1:19.
33. Gabryelewicz T., Religa D., Styczynska M., Peplonska B., Pfeffer A., Wasiak B., Luczywek E., Golebiowski M., Androsiuk W., Czyzewski K., Przekop I., Barcikowska M. Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype. Dement. Geriatr. Cogn. Disord. 2002, 14:208-212.
34. Gilley D.W., Wilson R.S., Beckett L.A., Evans D.A. Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. J. Am. Geriatr. Soc. 1997, 45:1074-1079.
35. Glatt S.J., Jonsson E.G. The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:149-154.
36. Go R.C., Perry R.T., Wiener H., Bassett S.S., Blacker D., Devlin B., Sweet R.A. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 139B:28-32.
37. Grunblatt E., Zehetmayer S., Bartl J., Loffler C., Wichart I., Rainer M.K., Jungwirth S., Bauer P., Danielczyk W., Tragl K.H., Riederer P., Fischer P. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J. Psychiatr. Res. 2009, 43:298-308.
38. Harwood D.G., Barker W.W., Ownby R.L., St George-Hyslop P., Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease. Am. J. Geriatr. Psychiatry 1999, 7:119-123.
39. Herrmann N., Lanctot K.L. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?. Drug Saf. 2006, 29:833-843.
40. Herrmann N., Lanctot K.L. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can. J. Psychiatry 2007, 52:630-646.
41. Hirono N., Mori E., Yasuda M., Ikejiri Y., Imamura T., Shimomura T., Ikeda M., Hashimoto M., Yamashita H. Factors associated with psychotic symptoms in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1998, 64:648-652.
42. Hollingworth P., Hamshere M.L., Moskvina V., Dowzell K., Moore P.J., Foy C., Archer N., Lynch A., Lovestone S., Brayne C., Rubinsztein D.C., Lawlor B., Gill M., Owen M.J., Williams J. Four components describe behavioral symptoms in 1120 individuals with late-onset Alzheimer's disease. J. Am. Geriatr. Soc. 2006, 54:1348-1354.
43. Hollingworth P., Hamshere M.L., Holmans P.A., O'Donovan M.C., Sims R., Powell J., Lovestone S., Myers A., DeVrieze F.W., Hardy J., Goate A., Owen M., Williams J. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:841-848.
44. Hollingworth P., Sweet R., Sims R., Harold D., Russo G., Abraham R., Stretton A., Jones N., Gerrish A., Chapman J., Ivanov D., Moskvina V., Lovestone S., Priotsi P., Lupton M., Brayne C., Gill M., Lawlor B., Lynch A., Craig D., McGuinness B., Johnston J., Holmes C., Livingston G., Bass N.J., Gurling H., McQuillin A., Holmans P., Jones L., Devlin B., Klei L., Barmada M.M., Demirci F.Y., Dekosky S.T., Lopez O.L., Passmore P., Owen M.J., O'Donovan M.C., Mayeux R., Kamboh M.I., Williams J. Genome-wide association study of Alzheimer's disease with psychotic symptoms. Mol. Psychiatry 2011.
45. Holmes C., Levy R., McLoughlin D.M., Powell J.F., Lovestone S. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1996, 61:580-583.
46. Holmes C., Arranz M.J., Powell J.F., Collier D.A., Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum. Mol. Genet. 1998, 7:1507-1509.
47. Holmes C., Smith H., Ganderton R., Arranz M., Collier D., Powell J., Lovestone S. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J. Neurol. Neurosurg. Psychiatry 2001, 71:777-779.
48. Holmes C., Arranz M., Collier D., Powell J., Lovestone S. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 119B:40-43.
49. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
50. Jonsson E.G., Sillen A., Vares M., Ekholm B., Terenius L., Sedvall G.C. Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 119B:28-34.
51. Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 2009, 4:1073-1081.
52. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
53. Lappalainen J., Zhang L., Dean M., Oz M., Ozaki N., Yu D.H., Virkkunen M., Weight F., Linnoila M., Goldman D. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 1995, 27:274-279.
54. Lehtovirta M., Soininen H., Helisalmi S., Mannermaa A., Helkala E.L., Hartikainen P., Hanninen T., Ryynanen M., Riekkinen P.J. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996, 46:413-419.
55. Levy M.L., Cummings J.L., Fairbanks L.A., Sultzer D.L., Small G.W. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol. Psychiatry 1999, 45:422-425.
56. Liu C.Y., Hong C.J., Liu T.Y., Lin K.N., Wang P.N., Chi C.W., Chuang Y.Y., Liu H.C. Lack of association between the apolipoprotein E genotype and depression in Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 2002, 15:20-23.
57. Lopez O.L., Kamboh M.I., Becker J.T., Kaufer D.I., Dekosky S.T. The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology 1997, 49:794-797.
58. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 1996, 225:1068-1072.
59. Lyketsos C.G., Baker L., Warren A., Steele C., Brandt J., Steinberg M., Kopunek S., Baker A. Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. J. Neuropsychiatry Clin. Neurosci. 1997, 9:64-67.
60. Lyketsos C.G., Steele C., Galik E., Rosenblatt A., Steinberg M., Warren A., Sheppard J.M. Physical aggression in dementia patients and its relationship to depression. Am. J. Psychiatry 1999, 156:66-71.
61. Lyketsos C.G., Sheppard J.M., Steinberg M., Tschanz J.A., Norton M.C., Steffens D.C., Breitner J.C. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int. J. Geriatr. Psychiatry 2001, 16:1043-1053.
62. Mattson M.P., Maudsley S., Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004, 27:589-594.
63. Meeks T.W., Ropacki S.A., Jeste D.V. The neurobiology of neuropsychiatric syndromes in dementia. Curr. Opin. Psychiatry 2006, 19:581-586.
64. Mega M.S., Lee L., Dinov I.D., Mishkin F., Toga A.W., Cummings J.L. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2000, 69:167-171.
65. Middle F., Pritchard A.L., Handoko H., Haque S., Holder R., Bentham P., Lendon C.L. No association between neuregulin 1 and psychotic symptoms in Alzheimer's disease patients. J. Alzheimers Dis. 2010, 20:561-567.
66. Mirakhur A., Craig D., Hart D.J., McLlroy S.P., Passmore A.P. Behavioural and psychological syndromes in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2004, 19:1035-1039.
67. Monastero R., Mariani E., Camarda C., Ingegni T., Averna M.R., Senin U., Camarda R., Mecocci P. Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease. Acta Psychiatr. Scand. 2006, 113:59-63.
68. Murphy G.M., Taylor J., Tinklenberg J.R., Yesavage J.A. The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease. Am. J. Geriatr. Psychiatry 1997, 5:88-89.
69. Nacmias B., Tedde A., Forleo P., Piacentini S., Guarnieri B.M., Bartoli A., Ortenzi L., Petruzzi C., Serio A., Marcon G., Sorbi S. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol. Psychiatry 2001, 50:472-475.
70. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 2004, 23:540-545.
71. O'Brien J.T., Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J. Psychopharmacol. 2011, 25:997-1019.
72. Okochi T., Ikeda M., Kishi T., Kawashima K., Kinoshita Y., Kitajima T., Yamanouchi Y., Tomita M., Inada T., Ozaki N., Iwata N. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr. Res. 2009, 110:140-148.
73. Pearlson G.D., Ross C.A., Lohr W.D., Rovner B.W., Chase G.A., Folstein M.F. Association between family history of affective disorder and the depressive syndrome of Alzheimer's disease. Am. J. Psychiatry 1990, 147:452-456.
74. Poirier J., Sevigny P. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J. Neural Transm. 1998, Suppl 53:199-207.
75. Pritchard A.L., Harris J., Pritchard C.W., Coates J., Haque S., Holder R., Bentham P., Lendon C.L. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:123-126.
76. Pritchard A.L., Harris J., Pritchard C.W., Coates J., Haque S., Holder R., Bentham P., Lendon C.L. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol. Aging 2008, 29:341-347.
77. Pritchard A.L., Ratcliffe L., Sorour E., Haque S., Holder R., Bentham P., Lendon C.L. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2009, 24:1020-1025.
78. Proitsi P., Lupton M.K., Reeves S.J., Hamilton G., Archer N., Martin B.M., Iyegbe C., Hollingworth P., Lawlor B., Gill M., Brayne C., Rubinsztein D.C., Owen M.J., Williams J., Lovestone S., Powell J.F. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol. Aging 2010.
79. Proitsi P., Hamilton G., Tsolaki M., Lupton M., Daniilidou M., Hollingworth P., Archer N., Foy C., Stylios F., McGuinness B., Todd S., Lawlor B., Gill M., Brayne C., Rubinsztein D.C., Owen M., Williams J., Craig D., Passmore P., Lovestone S., Powell J.F. A multiple indicators multiple causes (MIMIC) model of behavioural and psychological symptoms in dementia (BPSD). Neurobiol. Aging 2011, 32:434-442.
80. Quaranta D., Bizzarro A., Marra C., Vita M.G., Seripa D., Pilotto A., Sebastiani V., Mecocci P., Masullo C. Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J. Alzheimers Dis. 2009, 16:173-180.
81. Ramachandran G., Marder K., Tang M., Schofield P.W., Chun M.R., Devanand D.P., Stern Y., Mayeux R. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology 1996, 47:256-259.
82. Reynolds G.P., Templeman L.A., Zhang Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:1021-1028.
83. Robert P.H., Verhey F.R., Byrne E.J., Hurt C., De Deyn P.P., Nobili F., Riello R., Rodriguez G., Frisoni G.B., Tsolaki M., Kyriazopoulou N., Bullock R., Burns A., Vellas B. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur. Psychiatry 2005, 20:490-496.
84. Robertson J., Curley J., Kaye J., Quinn J., Pfankuch T., Raber J. apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice. Neurobiol. Aging 2005, 26:637-643.
85. Sand P.G. A lesson not learned: allele misassignment. Behav. Brain Funct. 2007, 3:65.
86. Sato N., Ueki A., Ueno H., Shinjo H., Morita Y. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type. J. Alzheimers Dis. 2009, 17:441-448.
87. Scarmeas N., Brandt J., Albert M., Devanand D.P., Marder K., Bell K., Ciappa A., Tycko B., Stern Y. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002, 58:1182-1188.
88. Soininen H., Partanen K., Pitkanen A., Hallikainen M., Hanninen T., Helisalmi S., Mannermaa A., Ryynanen M., Koivisto K., Riekkinen P. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele. Neurology 1995, 45:391-392.
89. Spalletta G., Bernardini S., Bellincampi L., Federici G., Trequattrini A., Caltagirone C. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. Eur. J. Neurol. 2006, 13:176-182.
90. Steele C., Rovner B., Chase G.A., Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry 1990, 147:1049-1051.
91. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., Stefansson K. Neuregulin 1 and and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002, 71:877-892.
92. Sweet R.A., Nimgaonkar V.L., Kamboh M.I., Lopez O.L., Zhang F., Dekosky S.T. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch. Neurol. 1998, 55:1335-1340.
93. Sweet R.A., Nimgaonkar V.L., Devlin B., Lopez O.L., Dekosky S.T. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002, 58:907-911.
94. Sweet R.A., Devlin B., Pollock B.G., Sukonick D.L., Kastango K.B., Bacanu S.A., Chowdari K.V., Dekosky S.T., Ferrell R.E. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol. Psychiatry 2005, 10:1026-1036.
95. Tunstall N., Owen M.J., Williams J., Rice F., Carty S., Lillystone S., Fraser L., Kehoe P., Neill D., Rudrasingham V., Sham P., Lovestone S. Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's disease. Br. J. Psychiatry 2000, 176:156-159.
96. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., Piazza P.V., Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000, 408:199-203.
97. van der Flier W.M., Staekenborg S., Pijnenburg Y.A., Gillissen F., Romkes R., Kok A., Bouwman F.H., Scheltens P. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement. Geriatr. Cogn. Disord. 2007, 23:42-46.
98. Weiner M.F., Vega G., Risser R.C., Honig L.S., Cullum C.M., Crumpacker D., Rosenberg R.N. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biol. Psychiatry 1999, 45:633-638.
99. Williams H.J., Owen M.J., O'Donovan M.C. Is COMT a susceptibility gene for schizophrenia?. Schizophr. Bull. 2007, 33:635-641.
100. Woods D.L., Bushnell B., Kim H., Geschwind D., Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. Int. Psychogeriatr. 2009, 21:722-728.
101. Xie E., Zhu L., Zhao L., Chang L.S. The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Genomics 1996, 35:551-561.
102. Zdanys K.F., Kleiman T.G., MacAvoy M.G., Black B.T., Rightmer T.E., Grey M., Garman K.S., Tampi R.R., Gelernter J., van Dyck C.H. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology 2007, 32:171-179.
103. Zhang L., Fang Y., Zeng Z., Lian Y., Wei J., Zhu H., Jia Y., Zhao X., Xu Y. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. J. Alzheimers Dis. 2011.